» Articles » PMID: 17710100

Targeting Virulence: a New Paradigm for Antimicrobial Therapy

Overview
Journal Nat Chem Biol
Date 2007 Aug 22
PMID 17710100
Citations 538
Authors
Affiliations
Soon will be listed here.
Abstract

Clinically significant antibiotic resistance has evolved against virtually every antibiotic deployed. Yet the development of new classes of antibiotics has lagged far behind our growing need for such drugs. Rather than focusing on therapeutics that target in vitro viability, much like conventional antibiotics, an alternative approach is to target functions essential for infection, such as virulence factors required to cause host damage and disease. This approach has several potential advantages including expanding the repertoire of bacterial targets, preserving the host endogenous microbiome, and exerting less selective pressure, which may result in decreased resistance. We review new approaches to targeting virulence, discuss their advantages and disadvantages, and propose that in addition to targeting virulence, new antimicrobial development strategies should be expanded to include targeting bacterial gene functions that are essential for in vivo viability. We highlight both new advances in identifying these functions and prospects for antimicrobial discovery targeting this unexploited area.

Citing Articles

Orthogonally conjugated phthalocyanine-porphyrin oligomer for NIR photothermal-photodynamic antibacterial treatment.

Lian G, Zhao W, Ma G, Zhang S, Wu A, Wang L Commun Chem. 2025; 8(1):80.

PMID: 40087397 DOI: 10.1038/s42004-025-01470-w.


Dual-function regulator MexL as a target to control phenazines production and pathogenesis of Pseudomonas aeruginosa.

Yu Z, Wu Z, Liu D, Liu H, Zhang Y, Zheng Y Nat Commun. 2025; 16(1):2000.

PMID: 40011517 PMC: 11865548. DOI: 10.1038/s41467-025-57294-8.


Toward Virulence Inhibition: Beyond Cell Wall.

Kotliarova M, Shumkov M, Goncharenko A Microorganisms. 2025; 13(1).

PMID: 39858789 PMC: 11767696. DOI: 10.3390/microorganisms13010021.


Towards New Scaffolds for Antimicrobial Activity-In Silico/In Vitro Workflow Introducing New Lead Compounds.

Mangana M, Lambrinidis G, Kostakis I, Kalpaktsi I, Sagnou M, Nicolaou C Antibiotics (Basel). 2025; 14(1).

PMID: 39858297 PMC: 11763081. DOI: 10.3390/antibiotics14010011.


Advancing treatment strategies against MRSA: unveiling the potency of tubuloside A in targeting sortase A and mitigating pathogenicity.

Xu Y, Luan Y, Wang R, Su Z, Wang L, Liu Y World J Microbiol Biotechnol. 2025; 41(2):29.

PMID: 39789193 DOI: 10.1007/s11274-024-04185-7.